Johnson & Johnson (JNJ.US) submits application for potential blockbuster therapy
AInvestFriday, Aug 30, 2024 2:20 am ET
1min read
JNJ --

Johnson & Johnson (JNJ.US) announced that it has submitted a Biologics License Application (BLA) to the US FDA seeking global first approval of its investigational FcRn-targeting antibody therapy, nipocalimab, for the treatment of generalized myasthenia gravis (gMG). According to a previous press release, the therapy was the first FcRn inhibitor to demonstrate superiority over placebo in improving patient daily living activities (MG-ADL) scores when used in combination with standard of care (SOC) in antibody-positive gMG patients, including anti-AChR+, anti-MuSK+, and anti-LRP4+ patients. Given nipocalimab's potential to treat various autoimmune diseases, the therapy was ranked as one of the top 10 potential blockbuster pipeline therapies by industry media Evaluate earlier this year.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.